Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones

(marketscreener.com) Libmeldy® revenue totaled $5.8M in Q4 2022 and $18.8M for the full year with commercial expansion activities continuing in Europe Clinical Type B meeting with U.S. FDA to take place in early 2023 prior to OTL-200 BLA submission Ended 2022 with approximately $144M in cash and investments and reduced burn rate to support operations into Q2...https://www.marketscreener.com/quote/stock/ORCHARD-THERAPEUTICS-PLC-46901491/news/Orchard-Therapeutics-Highlights-Recent-Progress-Across-HSC-Gene-Therapy-Portfolio-and-Outlines-Key-2-42691446/?utm_medium=RSS&utm_content=20230109